Background: Frontotemporal dementia (FTD) has been linked to the microtubule associated protein tau (MAPT) gene region of chromosome 17. However, many chromosome-17 linked FTLDs do not have MAPT mutations or tau protein deposits, but have ubiquitin positive, tau and alphasynuclein negative inclusions. Mutations in the progranulin (PGRN) gene, located 1.7 Mb from MAPT at 17q21.31, were recently discovered in some of these individuals. The pathologic phenotype in all cases has thus far included ubiquitinated neuronal intranuclear inclusions (NIIs) and neuronal cytoplasmic inclusions (NCIs).
studies to be the most common subtype. [12] [13] [14] [15] Various pathogenic mutations in the progranulin (PGRN) gene were recently reported in individuals with FTLD-U linked to chromosome 17q21 and without mutations in the tau gene MAPT, located 1.7 Mb from the PGRN gene on chromosome 17q21. 16, 17 Later, PGRN mutations were also identified in the HDDD2, 18 PPA1 and PPA3, 19 and HDDD1 20 families, in families with corticobasal syndrome, 21, 22 and in familial and sporadic patients from large FTLD populations. [23] [24] [25] Those autopsied have all demonstrated pathology consistent with FTLD-U including NCIs and NIIs. 16, 17, 23 To further study the possible relationships between PGRN mutations, clinical phenotypes, and neuropathology, we compare the clinical history and neuropathology in 12 FTLD-U cases: 4 with and 8 without PGRN mutations. All four cases with PGRN mutations had Ub-NIIs. In contrast to a recent article, 26 but in agreement with another recent article, 23 5 of our 8 cases without PGRN mutations also had Ub-NIIs. The pathology of FTLD-U cases with PGRN mutations is associated with more frequent frontal ubiquitinated cytoplasmic inclusions (NCIs) and dystrophic neurites, less frequent dentate gyrus NCIs, and more frequent striatal NIIs compared to FTLD-U cases without PGRN mutation.
METHODS Choice of cases. From a total of 441 autopsied cases accessioned over a period of 10 years, and a total of 1,323 subjects clinically evaluated over the same time period, we chose for genetic analysis 12 cases clinically diagnosed with FTD and PPA that were also pathologically diagnosed at autopsy with FTLD-U, and for which sufficient clinical and pathologic information and DNA or frozen tissue was available. A total of 415 cases were eliminated because they did not have a pathologic diagnosis of FTLD-U. Of the remaining 26 cases, 11 were eliminated because they did not have sufficient clinical information, and 3 additional cases were eliminated because they did not have DNA available, leaving 12 cases included in this study. Cases were analyzed on the basis of the autopsy permit, which states that tissues may be used for research and teaching, as per the Northwestern IRB.
Clinical evaluation. Nine of the 12 subjects were enrolled in the Clinical Core of the Cognitive Neurology and AD Center (CNADC) at Northwestern University Feinberg School of Medicine on an Institutional Review Board protocol approved at Northwestern University. All subjects had given written informed consent to contribute clinical data and tissue specimens, including brain donation. Participants enrolled in the clinical core underwent a comprehensive neurologic and neuropsychological evaluation. A diagnosis of the behavioral variant of FTD was made by a neurologist using criteria outlined by the most recent work-group consensus statement on frontotemporal lobar degeneration, and was based on performance on neuropsychological tests and a comprehensive clinical evaluation. 3 A diagnosis of PPA was made on the basis of performance on neuropsychological tests, a comprehensive clinical evaluation, and the criteria outlined by Mesulam. 27 Once enrolled, patients were followed on an annual basis either in person or by phone until the time of their death.
Neuropathologic evaluation. Autopsies were performed by the Neuropathology Core of the Northwestern CNADC. Briefly, all brains were evaluated grossly for atrophy, ventricular dilatation, pallor of pigmented nuclei, and specific lesions if any, sliced fresh, and portions frozen for future biochemical and genetic studies. The remainder was fixed in 4% paraformaldehyde at 4°C for 30 hours and then placed in increasing concentrations of sucrose, and ultimately stored in 40% sucrose and preservative. Brain regions sampled included frontal, temporal, parietal, and occipital cortex, anterior and posterior hippocampus, amygdala, striatum, basal ganglia, thalamus with subthalamic nucleus, cerebellum, midbrain, pons, and medulla at the level of the hypoglossal nucleus. In most cases spinal cord was not available but uppermost cervical cord from lower brainstem was sampled. Tissue sections for paraffin embedding were rinsed in water and post-fixed overnight in formalin. Five micron sections were stained with H-E, phosphorylated tau (AT8, Pierce-Endogen, Rockford, IL), ubiquitin (DAKO polyclonal, Carpinteria, CA), alpha-synuclein (LB509, Zymed-Invitrogen, Carlsbad, CA), Abeta (4G8, Signet, Dedham, MA), and thioflavine-S, and floating sections were stained with Gallyas. They were evaluated microscopically for astrocytosis, superficial microvacuolation, and depopulation of pigmented nuclei. Cases were evaluated for Alzheimer disease (AD) with thioflavine-S, Gallyas, AT8, and Abeta 4G8, and Lewy body pathology with alpha-synuclein, and for non-Alzheimer-type deposits of tau, alpha-synuclein, and ubiquitin deposits. Cases were diagnosed with FTLD-U (Groups 1 and 2) when ubiquitinated NCIs, DNs, and NIIs were present, and FTLD-MND (Group 3) when FTLD-U was associated with clinical and pathologic motor neuron disease, according to currently accepted criteria. 6 Although in most cases the spinal cord was not sampled, neuronal loss and gliosis, Bunina bodies, and ubiquitinated skein-like inclusions and Lewy-like bodies in the hypoglossal nucleus was interpreted as evidence of lower motor neuron involvement in amyotrophic lateral sclerosis (ALS). All ubiquitin pathology was semi-quantitated as absent (0), mild or sparse (1ϩ), moderate (2ϩ), or severe or frequent (3ϩ).
Genetic analysis. Genomic DNA was isolated from brain tissue using standard protocols. PGRN sequencing analyses were performed using PCR and sequencing methods previously described. 16 Genetic analysis for SOD1 and VCP mutations was not performed. The four cases with PGRN mutations, all of which had pathologic FTLD-U, were designated as Group 1.
RESULTS Clinical phenotype. Cases were grouped on the basis of PGRN mutation analysis results, and presence or absence of clinical and pathologic ALS, into Group 1 (FTLD-U with PGRN mutations), Group 2 (FTLD-U without PGRN mutations), and Group 3 (FTLD-MND without PGRN mutations). Group 1 (n ‫؍‬ 4). Case 1. Case 1 was a right-handed man clinically diagnosed with FTD-bv at age 57. Initial symptoms included word finding difficulties and a gradual loss of the ability to write. Impaired judgment, disinhibition, and loss of insight also emerged within the first 2 years of symptom onset and therefore he was given a clinical diagnosis of FTD-bv. Brain MRI showed predominately left centrum semiovale hyperintensities. PET scan showed left frontal-temporal-parietal hypometabolism. Neurologic examination and CSF and other laboratory tests were all normal. Mini-Mental State Examination (MMSE) score at the initial examination 1.5 years after onset was 15/30 and his Activities of Daily Living Questionnaire (ADLQ) score was 64%, corresponding to the moderately impaired range (higher scores on this scale represent greater impairment). Past medical history was unremarkable with the exception of a mild concussion sustained approximately 10 years before the onset of symptoms. There was no family history of FTD-or PPA-like syndromes, but his mother had a clinical diagnosis of dementia in her 70s, one brother had a diagnosis of PD, and one son had a history of early developmental learning disability. Two years after symptom onset, the patient was completely mute, but appeared to retain relatively good comprehension. He required supervision with all activities of daily living, mainly as the result of impairments in judgment. Neurologic examination remained negative for fasciculations and lateralized sensorimotor findings. He was placed in a nursing home 2.5 years after onset and was no longer testable, and his ADLQ score was severely impaired (95%). Symptom course was rapid (4 years from purported onset) and the patient died at the age of 61; cause of death was pneumonia. Case 2. Case 2 was a right-handed woman with a history of PPA beginning at age 56. Symptoms began with gradually progressive word finding difficulties in conversation and 2 years after the onset she was limited to single word utterances. Neurologic sensorimotor examination 2 years after onset was notable only for right-sided posturing during complex gait. MMSE was 24/30 and her ADLQ score was in the minimally impaired range (8%). Medical history was unre-markable and there was no family history of dementia, developmental learning disability, or other neurologic disorders. Her father died at age 56, the age at which she first experienced symptoms, of a myocardial infarction. Neither of her father's parents was remembered as having dementia. Neuroimaging done within the first year of symptom onset showed a normal brain MRI with the exception of mild bilateral small vessel disease. A SPECT study revealed decreased perfusion of the left frontotemporal region. Her course was relatively rapid, MMSE done 3 years after onset was 13/30 and her ADLQ score was indicative of moderate impairment (28%). Four years after onset she demonstrated complete mutism, severely impaired language comprehension, and complete dependence on assistance for all activities of daily living (MMSE ϭ 0/30; ADLQ ϭ 95%). She had a urinary tract infection preterminally, and died at age 61. Case 3. Case 3 was a right-handed man with a history of PPA beginning at age 53. Initial symptoms were confined to word finding difficulties. Over the next several years he developed additional symptoms consisting of problems in writing, reading, and comprehension of speech. However, he remained independent in all activities of daily living, including piloting his own airplane, for the first 3 years. Annual neurologic examinations for 6 years after onset were all normal. Neuroimaging done 3 years after the onset showed left perisylvian atrophy. MMSE completed 4 years after onset was only mildly impaired (26/30), but 2 years later had declined substantially due to progressing language impairment (14/30). The ADLQ scores were 20% 4 years and 30% 6 years after onset, remaining within the mildly impaired range. Language symptoms remained predominant throughout the course of his illness and he remained independent in activities of daily living that did not depend on language abilities until approximately 7 years after onset when he began to develop significant behavioral disturbances, consisting of paranoia, aggression, and stealing. He was institutionalized and was no longer able to be tested. His mother had been diagnosed with dementia in her 50s and died at age 64. No other family history of dementia was noted. The subject died at age 61; cause of death was unknown.
Case 4. Case 4 was a right-handed man with a history of FTD beginning at age 60. Initial symptoms were predominantly in the area of personality and behavior. He was seen 3 years after the purported onset of symptoms, 1 year before death. His MMSE at that time was moderately impaired (21/30), but his ADLQ score was indicative of more severe functional decline (69% impairment). Neurologic examination was notable only for hypomimia. Brain MRI showed bilateral atrophy mainly within the frontal and temporal lobes and a PET scan was normal. His course was rapid and he died at age 64, cause unknown. Group 2 (n ‫؍‬ 5). Case 5. Case 5 was a righthanded woman with a history of FTD beginning at age 65. Presenting symptoms included obsessive compulsive tendencies and other unusual behaviors. Two years after the onset, the patient was noted to be disinhibited, impulsive, and inappropriate in social interactions. MMSE was mildly impaired (25/30), and ADLQ score was in the moderately impaired range (38%). Initial brain MRI and neurologic evaluation were both unremarkable. There was a history of ALS without dementia in her father and brother. The patient did not have clinical symptoms of ALS, i.e., no weakness, spasticity, or fasciculations. She was last evaluated approximately 6 months before death and at that time her MMSE was severely impaired (12/30) and her ADLQ indicated a moderate to severe level of impairment (56%). The subject died 5 years after onset at age 70; cause of death was unknown. Case 6. Case 6 was a right-handed woman with a history of PPA beginning at age 63. Initial neuropsychological examination done 2 years after the onset of symptoms showed moderate naming impairment, mild difficulties in attention, but normal visuospatial abilities, retentive memory, executive functions, and comportment. MMSE was mildly impaired (22/30) and activities of daily living were moderately impaired (ADLQ ϭ 46%) mainly as the result of language difficulties. Mild right-sided intention tremor was noted within 2 years after the onset of symptoms, and over the following year she developed bilateral rigidity and tremor and was given a diagnosis of corticobasal degeneration. Brain MRI done at that time was unremarkable. Language symptoms progressively worsened over time, but she continued to demonstrate intact memory 3 years after onset. Her last evaluation was 1 year before death and both MMSE (11/30) and ADLQ impairment level (90%) were severely impaired, due to motor and language problems. There was no family history of dementia. She died at age 68; cause of death was unknown.
Case 7. Case 7 was a man with a history of FTD beginning at age 59. This subject was acquired through the community and clinical symp-toms are based on the available medical records. According to the initial neurology report 1 year after symptom onset, his initial presentation consisted of impulsivity, overeating, and perseverative behaviors, but relatively intact memory. MMSE was mildly impaired (23/30). Brain MRI and neurologic examination were both normal. Family history was significant for one brother with a clinical diagnosis of Pick disease, but no autopsy. He died 5 years after onset, at age 64, of pneumonia.
Case 8. Case 8 was a man with a history of dementia beginning at age 74. This subject was never evaluated clinically, but according to minimal records obtained at the time of autopsy, developed symptoms of "dementia" beginning at age 74. He died 10 years later, cause unknown. No information is available regarding his family history or clinical course. Case 9. Case 9 was a right-handed man with history of FTD beginning at age 66, based on a reported history of significant behavioral changes. He was initially seen 8 years after the onset of symptoms at age 74 and at that time was severely impaired (MMSE ϭ 3/30; ADLQ ϭ 95% impairment). EEG showed bitemporal slowing and an MRI showed evidence of an occipital stroke. Neurologic examination was remarkable for postural instability and left homonymous hemianopsia. Two first-degree relatives had a reported history of unspecified dementia, but no other information was available. The patient died 13 years after onset at age 79, cause of death was unknown.
Group 3 (n ‫؍‬ 3). Case 10. Case 10 was a righthanded woman with a history of PPA and ALS beginning at age 65. Initial signs included stuttering progressing to word finding difficulties in conversation, but intact comprehension. Initial neurologic examination 2 years after onset revealed facial and palate elevation weakness. MMSE was severely impaired (13/30) primarily due to expressive language problems, but she only demonstrated problems in ADLs as the result of language impairment (ADLQ ϭ 39%). She continued to live alone for 2 years after onset. SPECT scan showed mild reduction in left anterior temporal perfusion compared to the right. Within 3 years she had developed widespread fasciculations and was diagnosed with ALS. Language symptoms had progressed to complete mutism and severe comprehension impairment and she was no longer testable. She required assistance with all activities of daily living (ADLQ impairment level ϭ 75%). Her mother had a clinical di-agnosis of AD at age 87 and was still alive when the patient died at age 68 in her sleep. Her father had a diagnosis of "organic brain syndrome" and died at age 74. Case 11. Case 11 was a right-handed man with a history of FTD and ALS beginning at age 64. Significant personality changes were noted at onset including social withdrawal, lack of motivation, diminished concern about his failing competence, and carelessness in social and personal responsibilities. Brain MRI showed atrophy of the right temporal lobe. An EEG and comprehensive laboratory workup were normal. Within 1 year of the onset of behavioral symptoms, fasciculations were apparent on sensorimotor examination and the patient was diagnosed with ALS. MMSE 1 year after onset was only mildly reduced (27/30) as were his activities of daily living (ADLQ ϭ 33%). Family history was negative. He died at age 66; specific cause of death not known. Case 12. Case 12 was a right-handed man with a history of FTD and possible ALS beginning at age 58. Symptom onset was characterized by decreased judgment resulting in financial losses at work, reduced initiative, and emotional detachment. He also developed an increased craving for sweets and gained 20 pounds within 1 year. Very mild left spastic hemiparesis suggested the possibility of early ALS. Brain MRI showed bilateral frontal and temporal atrophy. An EEG and comprehensive laboratory workup were normal. Family history was notable for a father who died at age 70 of ALS. He was fully dependent for all activities of daily living prior to his death 5 years after onset at age 62 of respiratory failure.
Group comparisons. Although statistical comparisons are not feasible given the small sample size, the average age at onset was younger (56.5 years) in Group 1 compared to both Groups 2 (65.4 years) and 3 (62 years). Motor neuron disease was absent in the cases with PGRN mutations. All four cases with PGRN mutations had apolipoprotein E (APOE) 3/3 genotypes, but in this small study, the significance of this relationship is unclear. No consistent differences between the groups in gender or family history were apparent. Table 1 
is a comparison of demographic and clinical variables.
Neuropathologic phenotype. The 12 cases were chosen because they had the pathology of FTLD-U or FTLD-MND, and thus by definition share the presence of tau and alpha-synuclein negative, ubiquitin positive neuronal cytoplasmic in- clusions (NCI) and dystrophic neurites (DN) in superficial frontal or temporal cortex or both, hippocampal dentate gyrus, or striatum. Clinical and pathologic ALS, including upper and lower motor neuron loss and Bunina bodies and ubiquitinated skein-like inclusions in lower motor neurons, was present in the three cases in Group 3 (FTLD-MND cases without PGRN mutations).
The spinal cords were not available for examination in Groups 1 and 2; however, the hypoglossal nucleus had no neuronal loss or Bunina bodies and ubiquitin immunostains revealed no skeinlike inclusions or Lewy body-like inclusions. Sparse neurofibrillary tangles were present in nine cases, reaching a maximum Braak stage of II, except in one case that had concomitant AD (CERAD C, Braak V). FTLD-U pathology. There was no significant difference in frontal, temporal, and striatal atrophy or frontal and temporal neuronal loss and gliosis between groups. There was more neuronal loss and gliosis in hippocampus, amygdala, and subiculum in Groups 2 and 3 than in Group 1. Thalamic neuronal loss and gliosis was similar in all groups. Temporal superficial microvacuolation was greatest in Group 1 (figure 1) .
Although statistical comparisons are not valid given the small sample size, certain differences between groups are intriguing. Table 2 shows the semiquantitative data for the most significant comparisons. Densities of dentate gyrus ubiquitinated NCIs were least in Group 1 (figure 2), while densities of frontal and temporal NCIs and DNs (figure 3) and temporal and striatal DNs were greatest in Group 1. There was no difference in densities of dentate gyrus DNs or striatal NCIs among the three groups. Characteristic fusiform or cigar-shaped, ubiquitin positive NIIs were found in all four Group 1 cases ( figure 4) . Four of the five Group 2 cases and one case from Group 3 also had ubiquitin positive NIIs. In Group 1, there were more NIIs in frontal lobe and striatum. Striatal atrophy was greatest in Group 1. Two of the three Group 3 cases had asymmetry of cortical atrophy; this was present in only one case in each of the other two groups. The average brain weight was greatest in Group 3. There was no difference between groups in neuronal loss and gliosis in striatum, substantia nigra, or pons, or in substantia nigra pallor or densities of ballooned neurons.
The averages of the semiquantitative estimates of severity of the neuropathology in each group are summarized in table 2.
PGRN mutation analysis. PGRN sequencing analysis was performed in 12 pathologically diagnosed FTLD-U cases, resulting in the identification of three different PGRN null mutations in four cases (Cases 1 and 2 have been previously reported 23 ). Case 3 has an exon 7 splice-site mutation, c.709-2AϾG, that is likely to result in the skipping of exon 7 leading to frameshift and a premature termination codon in exon 8 (p.Ala237TrpfsX4). This mutation has also been identified in family HDDD1, 20 and in a family with behavioral variant FTD. 25 Cases 1 and 4 carried the common c.1477CϾT (p.Arg493X) PGRN mutation that has been reported in 11 additional US FTLD-U individuals with and without family histories of dementia. [23] [24] [25] Case 2 carried the c.675_676delCA (p.Ser226TrpfsX28) mutation in exon 6. In addition to the two pathogenic mutations, a silent polymorphism c.708CϾT (p.Asn236Asn) was observed in the genomic sequencing of Case 10. This CϾT transition was observed at the last nucleotide of exon 6, and was not observed in 200 North American controls. Subsequent sequence analysis of the cDNA confirmed the presence of both wild-type and mutant mRNA, and therefore, we presume this polymorphism to be a rare benign sequence variant. DISCUSSION Thus far PGRN mutations have been found in screening familial cases of FTLD-U showing linkage to chromosome 17q, [16] [17] [18] 22 in familial PPA, 19 and more recently in screening both a large pathologic FTLD-U series 23 and a large clinical FTD series. 24, 25 The three different PGRN mutations identified in four individual cases presented in this study were found by screening 12 familial and sporadic cases with FTLD-U pathology with and without NIIs. Case 5's family history is suspicious for a familial FTD-MND and we cannot exclude the possibility that Case 5 represents variable expressivity of what is posited to be a clinicopathologic spectrum of disease. 28, 29 Ubiquitinated NIIs were first described in tau and alpha synuclein negative motor neuron disease inclusion dementia (MNDID, without MND), now most often termed FTLD-U. 30 Some researchers have reported them to be specific for familial FTLD-U 31-34 while others have reported their presence in both familial and sporadic FTLD-U, with and without clinical and pathologic ALS. 35 Ubiquitinated NIIs are now described as characteristic of, but not specific to, individuals with PGRN mutations and linkage to chromosome 17q in the absence of MAPT mutations. [16] [17] [18] Ubiquitin positive NIIs were indeed present in our four PGRN mutation carriers but were also present in five of eight cases without PGRN mutations, suggesting that ubiquitinated NIIs may be a highly sensitive, but rather nonspecific marker for PGRN mutations. This is different from another report in which no NIIs were found in cases testing negative for PGRN mutations. 26 The clinical evaluations of our cases revealed younger ages at onset and death in Group 1 than either of the other two groups. Duration of disease from purported onset to death was shortest in Group 3, which can likely be explained by the unfortunate complications of MND. Interestingly, there appears to be no difference in family history between groups.
It is interesting that PGRN mutations are null mutations that result in little or no transcription of progranulin protein from one allele, indicating that the FTLD-U clinical and pathologic phenotype is related to haploinsufficiency, or a decrease in normal progranulin. Progranulin is believed to be a protein with roles in tumorigenesis, angiogenesis, and cell growth. 36, 37 The neurodegenerative phenotype is likely related to a decrease in the trophic role of progranulin. Several investigators have been attempting to identify the aggregated protein in the ubiquitinated inclusions in order to further elucidate the pathophysiology of FTLD-U, and Neumann et al. recently identified TAR DNA-Binding protein 43 (TDP-43) as the ubiquitinated protein in all cases with FTLD-U and ALS pathology. 38 We are participating with this group in a multi-institutional collaboration to perform TDP-43 IHC on a large number of FTLD-U and FTLD-MND cases, which includes the cases in this article (manuscript in preparation). This landmark discovery may eventually allow a clearer understanding of the pathophysiology underlying FTLD-U with and without PGRN mutations, as well as illuminate the inter-relationship of FTLD-U and ALS. Since many familial FTLD-U cases do not have a PGRN mutation, it is likely that additional causal genes and genetic risk factors for FTLD-U exist. If these are found, it will be interesting to see if recently described specific pathologic subtypes of FTLD-U segregate with specific mutations in familial cases. 39, 40 As indicated in this study and others, 23,24 mutation analysis of cases that do not necessarily have a positive family history, or even those with a known negative family history, will also yield individuals with pathogenic PGRN mutations, presumably due to an incomplete or age-related disease penetrance.
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Ubiquitinated frontal cortex inclusions 
